Holderness Investments Co. Grows Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Holderness Investments Co. raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 22.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,391 shares of the medical research company’s stock after acquiring an additional 445 shares during the period. Holderness Investments Co.’s holdings in IQVIA were worth $470,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avior Wealth Management LLC increased its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after buying an additional 87 shares during the period. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the 4th quarter valued at approximately $33,000. Meeder Asset Management Inc. raised its stake in IQVIA by 353.7% in the third quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company’s stock valued at $58,000 after buying an additional 191 shares in the last quarter. Versant Capital Management Inc lifted its stake in IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in shares of IQVIA in the 4th quarter valued at $60,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE IQV opened at $184.13 on Friday. IQVIA Holdings Inc. has a 12 month low of $179.28 and a 12 month high of $256.29. The business’s 50 day moving average is $195.30 and its two-hundred day moving average is $209.18. The company has a market cap of $32.46 billion, a P/E ratio of 24.55, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on IQV. JPMorgan Chase & Co. reduced their target price on shares of IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Robert W. Baird decreased their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Morgan Stanley raised their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Stephens assumed coverage on IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target for the company. Finally, UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Five research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.